32
Participants
Start Date
June 24, 2024
Primary Completion Date
July 29, 2024
Study Completion Date
September 24, 2024
0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6)
Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6)
Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)
Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
0.08mg/kg DGPR1008 Injection Dose Group 4 (n=6)
Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
Dose Group 0 (n=8)
Within the specified time frame, dose escalation will be conducted. Intravenous infusions will be administered according to randomization, with subjects receiving either the corresponding dose or placebo.
The Affiliated Hospital of Qingdao University, Qingdao
Haitao Niu, MD
OTHER